FDA-Approved
Compounds with at least one FDA-approved pharmaceutical form. Research notes describe the compound class as studied in published literature.
Melanotan
Melanotan is the informal name for a family of synthetic alpha-MSH analogs originally developed for sunless tanning research. Two pharmaceutical descendants, afamelanotide (Scenesse) and bremelanotide (Vyleesi), are now FDA-approved for specific medical indications.
View research notes →
PT-141 (Bremelanotide)
PT-141 is the only FDA-approved on-demand treatment for hypoactive sexual desire disorder in premenopausal women. Here is what the RECONNECT trial data shows, what the research limitations are, and what it costs per milligram.
View research notes →
Semaglutide
Semaglutide has more large-scale human trial data behind it than almost any other peptide women research, and most of what's written about it still ignores the questions women actually ask: what it does to weight at midlife, what the PCOS research shows, and what a fair per-mg price looks like. Here is the evidence, the FDA picture, and the pricing, plainly.
View research notes →
Tesamorelin
Tesamorelin is a synthetic GHRH analog FDA-approved as Egrifta for excess visceral fat in people with HIV. Researchers also study it for liver fat reduction, metabolic health, and potential cognitive effects in populations with growth hormone dysregulation.
View research notes →
Tirzepatide
Tirzepatide targets two incretin receptors at once, and in the trial record that has meant the largest weight reductions yet measured in a drug study, results that matter to the women comparing it against semaglutide for midlife metabolic research. Here is what the evidence actually shows, including the heart failure finding that is especially relevant to women.
View research notes →